Table 1.
Experimental protocols
| Group | TBI | HSCT (cells/mouse) | CB | Additional treatment | Mouse strain | |
|---|---|---|---|---|---|---|
| A | 1 | 15 × 106 BMC | − | - | Congenic | |
| B | 1 | 15 × 106 BMC | − | 5 mM Diprotin A in vitro (15 min) | Congenic | |
| C | 1 | 10 × 106 BMC | − | - | Congenic | |
| D | 1 | 10 × 106 BMC | − | 5 mM Diprotin A in vitro (15 min) & in vivo (4 μM Diprotin A with BMiv & 5 μM Diprotin A sc 2×/day) | (72h) | Congenic |
| E | 1 | 10 × 106 BMC | − | Sitagliptin in vivo (4 mg/mouse/2×/day) | (72h) | Congenic |
| F | 1 | 15 × 106 BMC | + | - | Allogenic | |
| G | 1 | 15 × 106 BMC | + | Sitagliptin in vivo (4 mg/mouse/2×/day) | (48h) | Allogenic |